PL372303A1 - Nowe krystaliczne postaci soli hemi-wapniowej atorwastatyny i sposoby ich wytwarzania oraz nowe sposoby wytwarzania postaci I, VIII i IX soli hemi-wapniowej atorwastatyny - Google Patents
Nowe krystaliczne postaci soli hemi-wapniowej atorwastatyny i sposoby ich wytwarzania oraz nowe sposoby wytwarzania postaci I, VIII i IX soli hemi-wapniowej atorwastatynyInfo
- Publication number
- PL372303A1 PL372303A1 PL03372303A PL37230303A PL372303A1 PL 372303 A1 PL372303 A1 PL 372303A1 PL 03372303 A PL03372303 A PL 03372303A PL 37230303 A PL37230303 A PL 37230303A PL 372303 A1 PL372303 A1 PL 372303A1
- Authority
- PL
- Poland
- Prior art keywords
- calcium
- processes
- atorvastatin hemi
- novel
- forms
- Prior art date
Links
- FQCKMBLVYCEXJB-MNSAWQCASA-L atorvastatin calcium Chemical compound [Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 FQCKMBLVYCEXJB-MNSAWQCASA-L 0.000 title 2
- 239000013078 crystal Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
- C07D207/327—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35718102P | 2002-02-15 | 2002-02-15 | |
| US42532502P | 2002-11-12 | 2002-11-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL372303A1 true PL372303A1 (pl) | 2005-07-11 |
Family
ID=27760457
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL03372303A PL372303A1 (pl) | 2002-02-15 | 2003-02-19 | Nowe krystaliczne postaci soli hemi-wapniowej atorwastatyny i sposoby ich wytwarzania oraz nowe sposoby wytwarzania postaci I, VIII i IX soli hemi-wapniowej atorwastatyny |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1480950A4 (pl) |
| JP (2) | JP2005519076A (pl) |
| KR (1) | KR100724515B1 (pl) |
| CN (1) | CN100406436C (pl) |
| AU (1) | AU2003217653A1 (pl) |
| CA (1) | CA2475864A1 (pl) |
| DE (1) | DE03713610T1 (pl) |
| ES (1) | ES2241507T1 (pl) |
| HR (1) | HRP20040768A2 (pl) |
| IS (1) | IS7402A (pl) |
| MX (1) | MXPA04007939A (pl) |
| NO (1) | NO20043842L (pl) |
| PL (1) | PL372303A1 (pl) |
| WO (1) | WO2003070702A1 (pl) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7411075B1 (en) | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
| US7501450B2 (en) | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| MXPA04007995A (es) | 2002-02-19 | 2004-11-26 | Teva Pharma | Desolvatacion de solvatos de hemicalcio de atorvastatina. |
| EP1572643A2 (en) * | 2002-11-28 | 2005-09-14 | Teva Pharmaceutical Industries Ltd. | Crystalline form f of atorvastatin hemi-calcium salt |
| US20050271717A1 (en) | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
| US7655692B2 (en) | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
| JP2008506764A (ja) * | 2004-07-20 | 2008-03-06 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | ［Ｒ−（Ｒ＊，Ｒ＊）］−２−（４−フルオロフェニル）−β、δ−ジヒドロキシ−５−（１−メチルエチル）−３−フェニル−４−［（フェニルアミノ）カルボニル］−１Ｈ−ピロール−１−ヘプタン酸カルシウム塩（２：１）の新規形態 |
| JP2007505944A (ja) * | 2004-07-22 | 2007-03-15 | テバ ファーマシューティカル インダストリーズ リミティド | アトルバスタチンヘミカルシウム及びその調製の方法 |
| WO2006048894A1 (en) * | 2004-11-05 | 2006-05-11 | Morepen Laboratories Limited | Novel crystalline forms of atorvastatin calcium and processes for preparing them. |
| WO2006106372A1 (en) * | 2005-04-08 | 2006-10-12 | EGIS GYÓGYSZERGYÁR Nyilvánosan Müködö Részvénytársaság | New crystalline atorvastatin hemicalcium salt polymorph form |
| WO2007057755A1 (en) | 2005-11-21 | 2007-05-24 | Warner-Lambert Company Llc | Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-b,b-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-hept anoic acid magnesium |
| CA2633268A1 (en) * | 2005-12-13 | 2007-06-21 | Teva Pharmaceutical Industries Ltd. | Crystal form of atorvastatin hemi-calcium and processes for preparation thereof |
| US20070265456A1 (en) * | 2006-05-09 | 2007-11-15 | Judith Aronhime | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| EP2132171A4 (en) * | 2007-03-02 | 2010-11-17 | Dong A Pharm Co Ltd | NEW CRYSTALLINE FORMS OF PYRROLYLHEPTANIC ACID DERIVATIVES |
| KR20120011249A (ko) | 2010-07-28 | 2012-02-07 | 주식회사 경보제약 | 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법 |
| KR101324862B1 (ko) * | 2011-07-12 | 2013-11-01 | (주)에이에스텍 | 클로피도그렐 황산수소염의 구형 입자, 이를 포함하는 약학적 조성물 및 이의 제조방법 |
| EP3578546A1 (en) | 2013-11-15 | 2019-12-11 | Akebia Therapeutics Inc. | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof |
| CN105055357A (zh) * | 2015-09-25 | 2015-11-18 | 青岛华之草医药科技有限公司 | 一种治疗高胆固醇血症的药物阿托伐他汀钙组合物片剂 |
| KR101723783B1 (ko) * | 2017-02-24 | 2017-04-07 | 주식회사 경보제약 | 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법 |
| WO2025147589A1 (en) | 2024-01-05 | 2025-07-10 | Osanni Bio, Inc. | Implants, compositions, and methods for treating retinal diseases and disorders |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100431038B1 (ko) * | 1995-07-17 | 2004-05-12 | 워너-램버트 캄파니 엘엘씨 | 결정질[ｒ-(ｒ*,ｒ*)]-2-(4-플루오로페닐)-베타,델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-[(페닐아미노)카르보닐]-1ｈ-피롤-1-헵탄산 헤미 칼슘염 (아토르바스타틴) |
| HRP960313B1 (en) * | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
| US6087511A (en) * | 1996-07-16 | 2000-07-11 | Warner-Lambert Company | Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1) |
| CZ20021642A3 (cs) * | 1999-11-17 | 2003-05-14 | Teva Pharmaceutical Industries Ltd. | Polymorfní formy atorvastatinu vápenatého |
| EP1237865B1 (en) * | 1999-12-17 | 2005-11-16 | Pfizer Science and Technology Ireland Limited | A factory scale process for producing crystalline atorvastatin trihydrate hemi calcium salt |
| WO2001044181A1 (en) * | 1999-12-17 | 2001-06-21 | Warner Lambert Research And Development Ireland Limited | A process for producing crystalline atorvastatin calcium |
| CZ20031495A3 (cs) * | 2000-11-03 | 2004-01-14 | Teva Pharmaceutical Industries Ltd. | Forma VII hemi-kalcium atorvastatinu |
| IL156055A0 (en) * | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| AU2002224952B2 (en) * | 2000-12-27 | 2007-04-05 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of atorvastatin |
| WO2002057229A1 (en) * | 2001-01-19 | 2002-07-25 | Biocon India Limited | FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN) |
| SK16002003A3 (sk) * | 2001-06-29 | 2004-12-01 | Warner-Lambert Company Llc | Kryštalické formy vápenatej soli (2:1) [R-(R*,R*)]-2-(4-fluóro- fenyl)-beta,delta-dihydroxy-5-(1-metyletyl)-3-fenyl-4- [(fenylamino)karbonyl]-1H-pyrrol-1-heptánovej kyseliny (atorvastatín) |
| RU2304139C2 (ru) * | 2001-07-30 | 2007-08-10 | Д-р Редди'с Лабораторис Лтд | Кристаллические формы vi и vii кальциевой соли аторвастатина |
| UA77990C2 (en) * | 2001-12-12 | 2007-02-15 | Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid | |
| US20060122403A1 (en) * | 2002-09-03 | 2006-06-08 | Sanjay Suri | Atorvastatin calcium form vi or hydrates thereof |
| EP1572643A2 (en) * | 2002-11-28 | 2005-09-14 | Teva Pharmaceutical Industries Ltd. | Crystalline form f of atorvastatin hemi-calcium salt |
-
2003
- 2003-02-19 MX MXPA04007939A patent/MXPA04007939A/es unknown
- 2003-02-19 DE DE03713610T patent/DE03713610T1/de active Pending
- 2003-02-19 WO PCT/US2003/005384 patent/WO2003070702A1/en not_active Ceased
- 2003-02-19 JP JP2003569609A patent/JP2005519076A/ja not_active Withdrawn
- 2003-02-19 ES ES03713610T patent/ES2241507T1/es active Pending
- 2003-02-19 KR KR1020047012591A patent/KR100724515B1/ko not_active Expired - Fee Related
- 2003-02-19 AU AU2003217653A patent/AU2003217653A1/en not_active Abandoned
- 2003-02-19 EP EP03713610A patent/EP1480950A4/en not_active Withdrawn
- 2003-02-19 PL PL03372303A patent/PL372303A1/pl not_active Application Discontinuation
- 2003-02-19 CN CNB038082071A patent/CN100406436C/zh not_active Expired - Fee Related
- 2003-02-19 CA CA002475864A patent/CA2475864A1/en not_active Abandoned
- 2003-02-19 HR HR20040768A patent/HRP20040768A2/hr not_active Application Discontinuation
-
2004
- 2004-08-13 IS IS7402A patent/IS7402A/is unknown
- 2004-09-14 NO NO20043842A patent/NO20043842L/no not_active Application Discontinuation
-
2009
- 2009-06-08 JP JP2009137400A patent/JP2009235083A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA04007939A (es) | 2004-11-26 |
| WO2003070702A1 (en) | 2003-08-28 |
| HRP20040768A2 (en) | 2005-06-30 |
| IS7402A (is) | 2004-08-13 |
| EP1480950A1 (en) | 2004-12-01 |
| JP2005519076A (ja) | 2005-06-30 |
| KR100724515B1 (ko) | 2007-06-04 |
| EP1480950A4 (en) | 2005-05-18 |
| NO20043842L (no) | 2004-09-14 |
| ES2241507T1 (es) | 2005-11-01 |
| CN100406436C (zh) | 2008-07-30 |
| CN1646490A (zh) | 2005-07-27 |
| KR20040081202A (ko) | 2004-09-20 |
| CA2475864A1 (en) | 2003-08-28 |
| DE03713610T1 (de) | 2005-10-20 |
| JP2009235083A (ja) | 2009-10-15 |
| AU2003217653A1 (en) | 2003-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1480950A4 (en) | NOVEL HEMI-CALCIUM CRYSTALLINE FORMS OF ATORVASTATIN AND METHODS FOR THEIR PREPARATION, AS WELL AS NEW METHODS FOR THE PREPARATION OF FORORVASTATIN HEMI-CALCIUM FORMS I, VIII AND IX | |
| HUP0600538A3 (en) | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms | |
| PL377555A1 (pl) | Nowe krystaliczne postaci soli hemi-wapniowej atorwastatyny i sposoby ich wytwarzania oraz nowe sposoby wytwarzania innych postaci | |
| RS20130524A3 (en) | PROCEDURE FOR OBTAINING AMINO CROTONYL UNITS | |
| WO2003070725A3 (en) | Process for preparing indolinone derivatives | |
| AU2003230457A1 (en) | Compression of containers | |
| AU2003253188A1 (en) | Novel processes and intermediates for preparing triazolo-pyridines | |
| PT1620396E (pt) | Processo para a preparação de 2-cianopirrolidinas n-substituídas | |
| IL180708A0 (en) | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation | |
| AU2003297594A1 (en) | Crystalline form f of atorvastatin hemi-calcium salt | |
| AUPS329602A0 (en) | Fertilisation of soil | |
| AU2003216848A1 (en) | Deracemisation of amines | |
| AU2003217438A1 (en) | Novel crystalline forms of levetiracetam | |
| IL173012A0 (en) | Process and intermediate compounds useful in the preparation of statins, particularly atorvastatin | |
| AU2003225426A1 (en) | Process for the preparation of urea | |
| PL1685104T3 (pl) | Sposoby wytwarzania N-podstawionych ftalimidów | |
| HK1060294A (en) | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms | |
| AU2003238034A1 (en) | Novel use of imidazotriazinones | |
| AU2003235129A1 (en) | Process for preparation of 2-aminoketones | |
| AU2003200836A1 (en) | Method for the preparation of matairesinol | |
| AU2003296482A1 (en) | Tetracyclines as anti-fungal agents for treatment of ringworm | |
| GB2390088B (en) | Combustion process for the preparation of LiCoVO4 | |
| LT2004018A (en) | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms | |
| AU2003271712A1 (en) | Treatment of amm | |
| AU2003274043A1 (en) | Novel use of dioxocin-5-on derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |